Healthcare

Workhorse Health Introduces Innovative Mental Health Services for Ontario’s Caregivers and Their Families

TORONTO, May 28, 2024 (GLOBE NEWSWIRE) -- Workhorse Health is on a mission to bridge the gap in mental health…

6 months ago

 Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients…

6 months ago

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

Single healthcare-focused institutional investor $5 million upfront with up to an additional $10 million of gross proceeds upon the exercise in full…

6 months ago

Longeveron® to Attend BIO International Convention 2024

MIAMI, May 28, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular…

6 months ago

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet…

6 months ago

Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024

CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company…

6 months ago

Spectral AI to Participate in Benzinga’s “AI Unleashed: Exploring the Possibilities” Virtual Event

DALLAS, May 28, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence…

6 months ago

Evotec and CHDI Foundation Extend Strategic Drug Discovery Collaboration in Huntington’s Disease

Longstanding alliance between Evotec and CHDI to enable the development of therapeutics for Huntington's diseaseOne of Evotec's largest strategic drug…

6 months ago

Cloud DX Will Report First Quarter 2024 Results on May 30, 2024. Company will also extend the closing date of previously announced Private Placement

KITCHENER, ON / ACCESSWIRE / May 27, 2024 / Cloud DX (TSXV:CDX)(OTCQB:CDXFF), will post its Q1-2024 financial results after market…

6 months ago

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine)…

6 months ago